PL3134430T3 - Jednołańcuchowe białka agonisty receptora TRAIL - Google Patents
Jednołańcuchowe białka agonisty receptora TRAILInfo
- Publication number
- PL3134430T3 PL3134430T3 PL15721089T PL15721089T PL3134430T3 PL 3134430 T3 PL3134430 T3 PL 3134430T3 PL 15721089 T PL15721089 T PL 15721089T PL 15721089 T PL15721089 T PL 15721089T PL 3134430 T3 PL3134430 T3 PL 3134430T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor agonist
- agonist proteins
- chain trail
- trail
- chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 | |
| EP15721089.9A EP3134430B1 (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
| PCT/US2015/027270 WO2015164588A1 (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3134430T3 true PL3134430T3 (pl) | 2018-08-31 |
Family
ID=53055121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15721089T PL3134430T3 (pl) | 2014-04-23 | 2015-04-23 | Jednołańcuchowe białka agonisty receptora TRAIL |
Country Status (38)
| Country | Link |
|---|---|
| US (5) | US9908927B2 (pl) |
| EP (2) | EP3366699A1 (pl) |
| JP (2) | JP6523331B2 (pl) |
| KR (2) | KR102079919B1 (pl) |
| CN (2) | CN106459221B (pl) |
| AR (1) | AR100168A1 (pl) |
| AU (3) | AU2015249649B2 (pl) |
| BR (1) | BR112016024515B1 (pl) |
| CA (2) | CA2946402C (pl) |
| CL (1) | CL2016002683A1 (pl) |
| CR (1) | CR20160516A (pl) |
| CY (1) | CY1120281T1 (pl) |
| DK (1) | DK3134430T3 (pl) |
| DO (1) | DOP2016000284A (pl) |
| EC (1) | ECSP16089579A (pl) |
| ES (1) | ES2672368T3 (pl) |
| HR (1) | HRP20180950T1 (pl) |
| HU (1) | HUE038914T2 (pl) |
| IL (2) | IL248244B (pl) |
| LT (1) | LT3134430T (pl) |
| MA (2) | MA45069A (pl) |
| MX (2) | MX2016013858A (pl) |
| MY (1) | MY181986A (pl) |
| NO (1) | NO2776305T3 (pl) |
| PE (1) | PE20170299A1 (pl) |
| PH (2) | PH12020500377A1 (pl) |
| PL (1) | PL3134430T3 (pl) |
| PT (1) | PT3134430T (pl) |
| RS (1) | RS57153B1 (pl) |
| RU (1) | RU2699285C2 (pl) |
| SG (3) | SG10202111785VA (pl) |
| SI (1) | SI3134430T1 (pl) |
| SM (1) | SMT201800286T1 (pl) |
| TR (1) | TR201806912T4 (pl) |
| TW (2) | TWI683825B (pl) |
| UA (1) | UA118286C2 (pl) |
| UY (1) | UY36095A (pl) |
| WO (1) | WO2015164588A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2745801C2 (ru) * | 2015-05-04 | 2021-04-01 | Аподжиникс Аг | Одноцепочечные белки-агонисты рецептора cd40 |
| EP3364995B1 (en) | 2015-10-23 | 2021-08-04 | Apogenix AG | Single-chain cd27-receptor agonist proteins |
| AU2016341402B2 (en) * | 2015-10-23 | 2020-08-27 | Apogenix Ag | Single-chain GITR-receptor agonist proteins |
| JP6873119B2 (ja) * | 2015-10-23 | 2021-05-19 | アポジェニックス アーゲー | 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質 |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| CN109153711B (zh) * | 2016-03-01 | 2022-04-26 | 伊利诺伊大学理事会 | 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白 |
| US20190077870A1 (en) * | 2016-03-16 | 2019-03-14 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CA3027380A1 (en) * | 2016-06-13 | 2017-12-21 | Merrimack Pharmaceuticals, Inc. | Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| AU2018313253B2 (en) * | 2017-08-11 | 2024-09-26 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig L-asparaginase variants and methods of use |
| WO2019178438A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of cancer |
| TW202002952A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |
| US20230212260A1 (en) | 2020-05-15 | 2023-07-06 | Apogenix Ag | Multi-specific immune modulators |
| CA3217894A1 (en) | 2021-05-28 | 2022-12-01 | Gernot Stuhler | Recombinant proteinaceous binding molecules |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025277A1 (en) | 1999-10-07 | 2001-04-12 | Maxygen Aps | Single-chain antagonist polypeptides |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| MXPA03005036A (es) | 2000-12-07 | 2003-09-05 | Lilly Co Eli | Proteinas de fusion glp-1. |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2003234274A1 (en) * | 2002-04-26 | 2003-11-10 | California Institute Of Technology | D1-1 nucleic acids, polypeptides and related methods |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| WO2006109301A2 (en) | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| CA2692802C (en) | 2007-07-10 | 2017-05-30 | Oliver Hill | Tnf superfamily collectin fusion proteins |
| BRPI0913406A2 (pt) | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
| HRP20150425T1 (hr) | 2008-07-21 | 2015-06-05 | Apogenix Gmbh | Tnf sf jednolanäśane molekule |
| EP2350641B1 (en) | 2008-09-22 | 2014-09-24 | Amgen Inc. | A combination of a tnf alpha inhibitor, an iap inhibitor and a trail receptor agonist for use in treating cancer |
| CA2739663A1 (en) * | 2008-10-10 | 2010-05-15 | Anaphore, Inc. | Polypeptides that bind trail-r1 and trail-r2 |
| WO2010078966A1 (en) | 2009-01-09 | 2010-07-15 | Apogenix Gmbh | Fusion proteins forming trimers |
| CA2750533A1 (en) * | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| WO2011076781A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| JP2013523179A (ja) * | 2010-04-13 | 2013-06-17 | メディミューン，エルエルシー | フィブロネクチンタイプｉｉｉドメインに基づく多量体足場 |
| US9717803B2 (en) * | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
| SG11201500134QA (en) | 2012-07-18 | 2015-03-30 | Apogenix Gmbh | Composition comprising a mixture of cd95-fc isoforms |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272612A (en) | Single-chain proteins are agonists of the TRAIL receptor | |
| IL246355B (en) | p97–ids fused proteins | |
| SG11201704010UA (en) | Fibroin-derived protein composition | |
| GB201415344D0 (en) | Protein | |
| IL250502B (en) | New polypeptides | |
| HUE050893T2 (hu) | Protein | |
| GB201515745D0 (en) | Proteins | |
| GB201511787D0 (en) | Proteins | |
| IL248276A0 (en) | Carbohydrate binding proteins | |
| SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
| GB201513033D0 (en) | Proteins | |
| PL3099793T3 (pl) | Białko | |
| GB201517390D0 (en) | Protein variant analysis | |
| GB201504048D0 (en) | Material sampler | |
| GB201412797D0 (en) | Proteins | |
| GB201412646D0 (en) | Proteins | |
| GB201412648D0 (en) | Proteins | |
| GB201412649D0 (en) | Proteins | |
| GB201406894D0 (en) | Proteins | |
| GB201405955D0 (en) | Proteins | |
| GB201405952D0 (en) | Proteins | |
| GB201403912D0 (en) | Proteins | |
| GB201403913D0 (en) | Proteins | |
| GB201403915D0 (en) | Proteins | |
| GB201403914D0 (en) | Proteins |